Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB) registered a -18.96% decrease, still its new closing price is 73.08% up from the company’s 1 year high of 1.51.It posted -23.73% losses in previous 5 sessions and is now the subject of 3 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 0 buy or better ratings. The 0 stock analysts following this company have an average price target at $1.25, with individual PT in the $1.25-$1.25 range. The shares moved at $0.45, implying that brokerage firms see shares losing about -45.78% in twelve months time.
Navidea Biopharmaceuticals, Inc (NAVB) SEC Form 4 News
The stock is getting much attention these days as insiders are offloading shares while they posted a -29.69% fall year to date. A EVP, CFO, Treas & Sec’y at Navidea Biopharmaceuticals, Inc (NAVB) offloaded shares in a transaction closed on Tuesday December 01, 2015. LARSON BRENT L sold 12,500 shares in the company at $1.5 each and collected $18,001 in proceeds. LARSON BRENT L now owns 222,237 shares in the company after this transaction. A EVP, CFO, Treas & Sec’y in the company, LARSON BRENT L, disclosed a transaction on Monday November 02, 2015 that ended up generating $24,001 from the sale of 12,500 shares at $1.98 per share.
Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB) Upcoming Results on Tap
Navidea Biopharmaceuticals, Inc will next provide financial results for the June 2017 quarter. Stock analysts expect it to report per-share earnings of $0.50 in that period. Sales during the quarter are predicted to arrive at $5.39 million.
Navidea Biopharmaceuticals, Inc (NAVB) Brokerage Update
Over the last six months and over the last three months, the shares of Navidea Biopharmaceuticals, Inc (NAVB), have changed -16.67% and -47.67%, respectively.
